ArticlePloS one2016
Exploiting the CRISPR/Cas9 PAM Constraint for Single-Nucleotide Resolution Interventions.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- CRISPR/Cas9 Mediated Genome Editing for Enhancing Abiotic Stress Tolerance in Rice: An Omics Guided Perspective.Molecular biotechnology · 2026Review
- Understanding exceptional response: The role of MINDY1 SNP in CDK4/6 inhibitor therapy for ERHGG advances · 2026Article
- Unveiling the invisible genomic dynamics.Experimental & molecular medicine · 2025Review
- Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson's Disease.Cells · 2024Review
- STAT6-targeting antisense oligonucleotides against solitary fibrous tumor.Molecular therapy. Nucleic acids · 2024Article
- CRISPRingCancers · 2024Review
- Massively parallel evaluation and computational prediction of the activities and specificities of 17 small Cas9s.Nature methods · 2023Article
- Reduction of Tumor Growth with RNA-Targeting Treatment of the NAB2-STAT6 Fusion Transcript in Solitary Fibrous Tumor Models.Cancers · 2023Article
- Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Haplotyping by CRISPR-mediated DNA circularization (CRISPR-hapC) broadens allele-specific gene editing.Nucleic acids research · 2020Article
- Allele-specific genome targeting in the development of precision medicine.Theranostics · 2020Review
- Specificity Assessment of CRISPR Genome Editing of Oncogenic EGFR Point Mutation with Single-Base Differences.Molecules (Basel, Switzerland) · 2019Article
- Coevolutionary Couplings Unravel PAM-Proximal Constraints of CRISPR-SpCas9.Biophysical journal · 2019Article
- Review
- The applications of CRISPR/Cas system in molecular detection.Journal of cellular and molecular medicine · 2018Review
- Towards personalised allele-specific CRISPR gene editing to treat autosomal dominant disorders.Scientific reports · 2017Article
- Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1.Molecular therapy. Nucleic acids · 2017Article
- CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Guide RNA engineering for versatile Cas9 functionality.Nucleic acids research · 2016Review
- Optimization of genome editing through CRISPR-Cas9 engineering.Bioengineered · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
CRISPR/Cas9 is an enabling RNA-guided technology for genome targeting and engineering. An acute DNA binding constraint of the Cas9 protein is the Protospacer Adjacent Motif (PAM). Here we demonstrate that the PAM requirement can be exploited to specifically target single-nucleotide heterozygous mutations while exerting no aberrant effects on the wild-type alleles. Specifically, we target the heterozygous G13A activating mutation of KRAS in colorectal cancer cells and we show reversal of drug resistance to a MEK small-molecule inhibitor. Our study introduces a new paradigm in genome editing and therapeutic targeting via the use of gRNA to guide Cas9 to a desired protospacer adjacent motif.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.